Last summer, the European Society of Medical Oncology (ESMO) published recommendations on how to use next-generation sequencing in clinical practice.

The ESMO recommendations, included in the publication: „Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group”, are based on the analysis of clinical validity and economic sustainability related to the introduction of next generation sequencing (NGS) in clinical practice at 3 different levels: from a public health perspective, from the perspective of academic clinical research institutions and taking into consideration potential advantages or disadvantages for each individual patient. The review considers the eigh